Meeder Asset Management Inc. grew its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 113.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,853 shares of the biopharmaceutical company’s stock after buying an additional 8,950 shares during the quarter. Meeder Asset Management Inc.’s holdings in Bristol Myers Squibb were worth $1,022,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Meeder Advisory Services Inc. grew its stake in Bristol Myers Squibb by 21.7% in the 1st quarter. Meeder Advisory Services Inc. now owns 30,119 shares of the biopharmaceutical company’s stock valued at $1,827,000 after acquiring an additional 5,361 shares during the period. Hamel Associates Inc. acquired a new position in Bristol Myers Squibb during the first quarter worth $220,000. Dimensional Fund Advisors LP lifted its holdings in Bristol Myers Squibb by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after purchasing an additional 520,330 shares in the last quarter. Scarborough Advisors LLC purchased a new position in Bristol Myers Squibb during the first quarter valued at $109,000. Finally, Parallel Advisors LLC grew its position in shares of Bristol Myers Squibb by 6.6% in the first quarter. Parallel Advisors LLC now owns 30,078 shares of the biopharmaceutical company’s stock valued at $1,824,000 after purchasing an additional 1,868 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the stock. Weiss Ratings cut shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Bank of America cut their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Finally, Guggenheim reissued a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $61.25.
More Bristol Myers Squibb News
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer
- Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research
- Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research
- Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
- Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon
Bristol Myers Squibb Stock Down 0.7%
Shares of NYSE:BMY opened at $60.30 on Tuesday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The business has a fifty day moving average of $57.11 and a two-hundred day moving average of $57.85. The stock has a market cap of $123.14 billion, a P/E ratio of 16.94, a PEG ratio of 0.17 and a beta of 0.23.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same period last year, the business earned $1.80 earnings per share. Bristol Myers Squibb’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.
Bristol Myers Squibb Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.
Bristol Myers Squibb Profile
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Read More
- Five stocks we like better than Bristol Myers Squibb
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
